Cell type-dependent biomarker expression in adenoid cystic carcinoma: biologic and therapeutic implications.
BACKGROUND
Adenoid cystic carcinoma (ACC), a rare and progressive salivary malignancy, is characterized by cellular, morphologic, and clinical heterogeneity. The authors of this report hypothesized that the dual cellular composition of ACC plays an important role in biomarker evaluation, tumor biologic behavior, and response to therapy.


METHODS
To investigate the differential localization and expression of the c-Kit protein and the epidermal growth factor receptor (EGFR) protein, immunohistochemical analyses were performed on tissue arrays that were constructed from 199 tumors, and the results were correlated with clinicopathologic factors.


RESULTS
c-Kit expression was limited to the inner ductal epithelial cells, whereas EGFR expression was limited mainly to the outer myoepithelial cells in the majority of ACCs with tubular and cribriform patterns. In solid ACCs, c-Kit uniformly was positive, whereas EGFR consistently was negative. A significant statistical correlation was observed between c-Kit expression and a poor 3-year outcome, and EGFR expression was correlated with a better 3-year outcome.


CONCLUSIONS
The current findings underscored the importance of cellular subtype localization of biomarkers in the clinical and therapeutic stratification of patients with ACC.
Bell
Diana
D
Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Roberts
Dianna
D
Kies
Merrill
M
Rao
Pulivarthi
P
Weber
Randal S
RS
El-Naggar
Adel K
AK
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D003528:Carcinoma, Adenoid Cystic / Q000175:diagnosis*; D066246:ErbB Receptors / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D019009:Proto-Oncogene Proteins c-kit / Q000032:analysis*; D012468:Salivary Gland Neoplasms / Q000175:diagnosis*
D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D019009:Proto-Oncogene Proteins c-kit
Mod Pathol. 2003 Dec;16(12):1224-31
14681323
J Oral Pathol Med. 2006 May;35(5):286-91
16630292
Mod Pathol. 2009 Oct;22(10):1296-302
19617878
J Clin Oncol. 2003 Jun 15;21(12):2237-46
12748244
Arch Otolaryngol Head Neck Surg. 1999 Feb;125(2):149-52
10037280
Cancer Lett. 2000 Jun 1;154(1):107-11
10799746
Head Neck. 2002 Jul;24(7):632-6
12112535
J Pathol. 1995 Nov;177(3):253-8
8551387
J Clin Oncol. 2004 Nov 15;22(22):4514-22
15542802
Gynecol Oncol. 2003 Oct;91(1):9-14
14529657
Histopathology. 2008 Nov;53(5):567-77
18983466
Clin Lung Cancer. 2004 Dec;6 Suppl 1:S20-3
15638953
Am J Clin Pathol. 2004 Jul;122(1):70-7
15272532
Science. 1998 Jan 23;279(5350):577-80
9438854
Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34
15451219
Oncologist. 2002;7 Suppl 4:31-9
12202786
Int J Cancer. 2001 Jun 20;96(3):149-58
11410883
JAMA. 2003 Oct 22;290(16):2149-58
14570950
J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):249-60
16807804
Clin Cancer Res. 2008 Aug 15;14(16):5181-7
18698036
J Pathol. 2004 Mar;202(3):375-81
14991904
Am J Pathol. 2004 Jan;164(1):305-13
14695343
J Clin Oncol. 2002 Mar 15;20(6):1692-703
11896121
Laryngorhinootologie. 2002 Feb;81(2):98-105
11914946
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 May;95(5):586-93
12738950
Cold Spring Harb Symp Quant Biol. 2005;70:343-56
16869771
Mod Pathol. 1998 Aug;11(8):728-34
9720500
Head Neck. 2004 Sep;26(9):829-31
15350030
J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):379-91
14973383
Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232
7612182
Mod Pathol. 2008 Sep;21(9):1168-75
18587327
Cancer Cell. 2008 May;13(5):394-406
18455123
N Engl J Med. 2003 Mar 13;348(11):994-1004
12637609
Mod Pathol. 1999 Oct;12(10):956-60
10530560
Clin Cancer Res. 2001 Oct;7(10):2958-70
11595683
J Clin Oncol. 2005 Jan 20;23(3):585-90
15659505
Int J Oral Maxillofac Surg. 2004 Jan;33(1):25-31
14690656
J Clin Oncol. 2003 Oct 15;21(20):3798-807
12953099